Suppr超能文献

评估降解微米大小肿瘤球体所需的局部细胞毒性 T 淋巴细胞的数量。

Assessment of the number of local cytotoxic T lymphocytes required for degradation of micrometer-size tumor spheroids.

机构信息

The Institute of Physical and Chemical Research (RIKEN), Koyadai, RIKEN Cell Bank, Tsukuba Science City, Ibaraki, 305, Japan.

出版信息

Cytotechnology. 2001 Sep;37(1):31-40. doi: 10.1023/A:1016139010531.

Abstract

Adoptive immunotherapy with human cytotoxic T lymphocytes (CTL) is a promising cancer treatment. Previously we showed that human CTLs against various types of tumors can be efficiently produced by coculturing peripheral blood cells with target cells. The aims of this study were to simulate the interaction of CTLs and micrometer-size tumor tissues in vitro and to assess the required number of CTLs at local tumor sites for degradation of a tumor. Allogeneic CTLs against a human transitional cell carcinoma cell line and autologous CTLs against a renal cell carcinoma cell derived from a surgical specimen were generated. The cytotoxic activities of CTLs against tumor cells in monolayer culture and tumor spheroids formed in U-bottom 96-well culture plates were assessed. Both allogeneic and autologous CTLs showed greater destructive activity than lymphokine activated killer (LAK) cells against target tumor spheroids. CTLs inoculated at E/T ratios of 0.1 to 1 coexisted with the tumor spheroid for 5 to 6 days and then increased in number with apparently lethal activity against the tumor spheroid. In contrast to CTLs, the increase in LAK cell numbers was scarcely observed, and the proliferated LAK cells did not show cytotoxicity against the tumor spheroid. These observations suggest that, when a small number of CTLs reach a local tumor site, they can destroy micrometer-size tumors after considerable local proliferation.

摘要

过继性免疫疗法用人体细胞毒性 T 淋巴细胞(CTL)是一种很有前途的癌症治疗方法。以前我们已经证明,通过共培养外周血细胞与靶细胞,可以有效地产生针对各种类型肿瘤的人体 CTL。本研究的目的是模拟 CTL 与微米大小的肿瘤组织在体外的相互作用,并评估在局部肿瘤部位降解肿瘤所需的 CTL 数量。生成了针对人移行细胞癌细胞系的同种异体 CTL 和针对从手术标本中获得的肾癌细胞的自体 CTL。评估了 CTL 对单层培养的肿瘤细胞和在 U 形底 96 孔培养板中形成的肿瘤球体的细胞毒性活性。与淋巴因子激活的杀伤(LAK)细胞相比,同种异体和自体 CTL 对靶肿瘤球体均显示出更大的破坏活性。接种 E/T 比为 0.1 至 1 的 CTL 与肿瘤球体共存 5 至 6 天,然后数量增加,对肿瘤球体具有明显的致死活性。与 CTL 不同,几乎观察不到 LAK 细胞数量的增加,并且增殖的 LAK 细胞对肿瘤球体没有细胞毒性。这些观察结果表明,当少量 CTL 到达局部肿瘤部位时,它们可以在相当大的局部增殖后破坏微米大小的肿瘤。

相似文献

本文引用的文献

3
Prospects for adoptive T cell therapy.过继性T细胞疗法的前景。
Curr Opin Immunol. 1997 Oct;9(5):702-8. doi: 10.1016/s0952-7915(97)80052-0.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验